Continuum Advisory, LLC Blueprint Medicines Corp Transaction History
Continuum Advisory, LLC
- $778 Million
- Q3 2024
A detailed history of Continuum Advisory, LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Continuum Advisory, LLC holds 21 shares of BPMC stock, worth $2,363. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21
Previous 36
41.67%
Holding current value
$2,363
Previous $3,000
66.67%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding BPMC
# of Institutions
355Shares Held
60.7MCall Options Held
2.25MPut Options Held
1.18M-
Vanguard Group Inc Valley Forge, PA6.68MShares$752 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$748 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.39MShares$606 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA3.96MShares$446 Million0.07% of portfolio
-
State Street Corp Boston, MA2.77MShares$311 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $6.72B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...